Pegcetacoplan

In this video, Yasha S. Modi, MD, discusses the Charles L. Schepens, MD, Lecture presented at the American Academy of Ophthalmology meeting by Emily Y. Chew, MD, on macular telangiectasia.

In this video, Arshad M. Khanani, MD, MA, FASRS, discusses the results of the GALE open-label extension study of pegcetacoplan in patients with geographic atrophy presented at the American Academy of Ophthalmology meeting.

NEW ORLEANS — Pegcetacoplan slowed lesion growth and was well-tolerated when given monthly or every other month in patients with geographic atrophy secondary to age-related macular degeneration, according to a presenter at Academy ‘23.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Cedric Francois, MD, PhD, CEO of Apellis Pharmaceuticals, previews 3-year data investigating long-term treatment of geographic atrophy with Syfovre.

The FDA approval of Izervay has provided a second welcomed treatment option for geographic atrophy, with good efficacy and a favorable safety profile.

I do think that complement therapy can be considered for many patients with geographic atrophy, but the risks and benefits need to be thoroughly discussed with the patient.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Charles C. Wykoff, MD, PhD, discusses data from the GALE long-term extension study investigating Apellis Pharmaceuticals’ Syfovre for geographic atrophy.

Two-year results from the phase 3 OAKS and DERBY studies evaluating Syfovre for geographic atrophy showed clinically meaningful reduction of lesion growth with increasing effect over time.

A research letter published in JAMA Ophthalmology described the case of a patient with geographic atrophy who reported multiple small floaters after intravitreal injection of pegcetacoplan.

SEATTLE — In this video, Esther M. Bowie, MD, discusses research presented at the ASRS meeting on the long-term efficacy of pegcetacoplan as well as late-breaking reports of ocular inflammation associated with the treatment.